Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
NEW YORK, Dec. 20, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Biogen Inc. (NASDAQ:BIIB) securities between July 23, 2014 and July 23, 2015.
Click here to learn about the case: http://www.wongesq.com/pslra/biogen-inc. There is no cost or obligation to you.
According to the complaint, defendants employed devices, schemes and artifices to defraud, while in possession of material adverse non-public information, in an effort to assure investors of Biogen’s value and performance and continued substantial growth. In particular, the complaint alleges that the Company failed to disclose material information about the Company’s business, particularly in regards to their Tecfidera drug treatment.
In 2014, the MS Institute at Shepherd Center in Georgia, a prescriber of Tecfidera, began conducting blood tests of MS patients taking the drug. By August of that year, the Center began notifying Biogen that Tecfidera was causing low lymphocyte counts among approximately 30% of the Center’s MS patients taking the drug; eventually the Center stopped prescribing Tecfidera and transferred many of its patients to other therapies. Biogen, however, continued to tout the safety and growing sales of Tecfidera throughout the second and third quarter of 2014.
If you suffered a loss in Biogen you have until December 23, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/biogen-inc.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
